Denise Trone

Statistics

Publications

Citations

1.9K

H-Index

Active since

2012

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

Johns Hopkins University

University of Pennsylvania

University of Washington

Memorial Sloan Kettering Cancer Center

Denise Trone is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, oncology, and hematologic malignancy therapy.

Publications per year

2012–2024

Publications

Phase I Study of Quizartinib Administered Daily to Patients With Relapsed or Refractory Acute Myeloid Leukemia Irrespective of FMS-Like Tyrosine Kinase 3–Internal Tandem Duplication Status

Jörge E. Cortes, Hagop M. Kantarjian, James M. Foran et al. · Journal of Clinical Oncology · 2013 · 361 citations · Full text

Medicine, Hematology, Oncology +15

Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial

Jörge E. Cortes, Alexander E. Perl, Hartmut Döhner et al. · The Lancet Oncology · 2018 · 264 citations · Full text

Medicine, Hematology, Oncology +11

Repotrectinib in <i>ROS1</i> Fusion–Positive Non–Small-Cell Lung Cancer

Alexander Drilon, D. Ross Camidge, Sang‐We Kim et al. · New England Journal of Medicine · 2024 · 210 citations · Full text

Medicine, Oncology, Pharmacology +16

Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD–mutated, relapsed or refractory AML

Jörge E. Cortes, Martin S. Tallman, Gary J. Schiller et al. · Blood · 2018 · 151 citations · Full text

Medicine, Oncology, Pharmacology +15

Final Results of a Phase 2 Open-Label, Monotherapy Efficacy and Safety Study of Quizartinib (AC220) in Patients with FLT3-ITD Positive or Negative Relapsed/Refractory Acute Myeloid Leukemia After Second-Line Chemotherapy or Hematopoietic Stem Cell Transplantation

Mark J. Levis, Alexander E. Perl, Hervé Dombret et al. · Blood · 2012 · 141 citations

Medicine, Hematology, Oncology +15

1–5 of 24